Evidence map›Paper›PMID 29735897›Full record

ReviewFoods (Basel, Switzerland)2018

Nanoparticles and Controlled Delivery for Bioactive Compounds: Outlining Challenges for New "Smart-Foods" for Health.

MCarment Martínez-Ballesta, Ángel Gil-Izquierdo, Cristina García-Viguera, Raúl Domínguez-Perles

Abstract readReview
In one paragraph

Review in Foods (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

MCarment Martínez-BallestaDepartment of Plant Nutrition, Centro de Edafología y Biología Aplicada del Segura-Spanish Council for Scientific Research (CEBAS-CSIC), Campus de Espinardo 25, 30100 Espinardo, Murcia, Spain. mballesta@cebas.csic.es.
Ángel Gil-IzquierdoResearch Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, Centro de Edafología y Biología Aplicada del Segura-Spanish Council for Scientific Research (CEBAS-CSIC), Campus de Espinardo 25, 30100 Espinardo, Murcia, Spain. angelgil@cebas.csic.es.ORCID 0000-0001-7646-0386
Cristina García-VigueraResearch Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, Centro de Edafología y Biología Aplicada del Segura-Spanish Council for Scientific Research (CEBAS-CSIC), Campus de Espinardo 25, 30100 Espinardo, Murcia, Spain. cgviguera@cebas.csic.es.ORCID 0000-0002-4751-3917
Raúl Domínguez-PerlesResearch Group on Quality, Safety and Bioactivity of Plant Foods, Department of Food Science and Technology, Centro de Edafología y Biología Aplicada del Segura-Spanish Council for Scientific Research (CEBAS-CSIC), Campus de Espinardo 25, 30100 Espinardo, Murcia, Spain. rdperles@cebas.csic.com.ORCID 0000-0001-6232-712X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanotechnology is a field of research that has been stressed as a very valuable approach for the prevention and treatment of different human health disorders. This has been stressed as a delivery system for the therapeutic fight against an array of pathophysiological situations. Actually, industry has applied this technology in the search for new oral delivery alternatives obtained upon the modification of the solubility properties of bioactive compounds. Significant works have been made in the last years for testing the input that nanomaterials and nanoparticles provide for an array of pathophysiological situations. In this frame, this review addresses general questions concerning the extent to which nanoparticles offer alternatives that improve therapeutic value, while avoid toxicity, by releasing bioactive compounds specifically to target tissues affected by specific chemical and pathophysiological settings. In this regard, to date, the contribution of nanoparticles to protect encapsulated bioactive compounds from degradation as a result of gastrointestinal digestion and cellular metabolism, to enable their release in a controlled manner, enhancing biodistribution of bioactive compounds, and to allow them to target those tissues affected by biological disturbances has been demonstrated.

Indexed as

controlled releasehealthimproved functionalitynanoparticlesphytochemicalssmart-formulations

Identifiers

PMID29735897
PMCPMC5977092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.